文献速递神经技术与安全PETCT

应用68Ga-Pentixafor(Pars-Cixafor™)PET/CT对高级别胶质瘤趋化因子受体4(CXCR4)过表达的前瞻性评估

A Prospective Evaluation of Chemokine Receptor-4 (CXCR4) Overexpression in High-grade Glioma Using 68Ga-Pentixafor (Pars-Cixafor™) PET/CT Imaging.
PubMed 文献 · Acad Radiol · 2024-12-16

本研究回顾性纳入29例组织病理学确诊且MRI表现符合高级别胶质瘤的患者,在MRI后2周内行68Ga-Cixafor™ PET/CT评估CXCR4表达。视觉评分系统判定27/29(93.1%)为阳性;IV级病灶中位SUVmax 2.85显著高于III级病灶1.27(P=0.02),但中位TBR在IV级20与III级22.37之间无显著差异。作者认为68Ga-Cixafor™ PET的TBR具有极低皮质摄取,可能提升胶质瘤检出。

要点

  • 视觉评分系统判定29例中27例(93.1%)为68Ga-Cixafor™ PET/CT阳性。
  • IV级病灶中位SUVmax 2.85显著高于III级病灶1.27(P=0.02)。
  • IV级病灶中位TBR 20与III级病灶22.37之间无显著差异。

核心结论

  • 68Ga-Cixafor™ PET显示TBR具有极低皮质摄取,可能较常规影像方法显著提升胶质瘤检出,并可能结合CXCR4靶向放射性药物的治疗潜力用于改善诊断和个体化治疗策略。

研究设计与样本

  • 回顾性分析,纳入29例组织病理学确诊且MRI表现符合高级别胶质瘤的患者,均在MRI后2周内行68Ga-Cixafor™ PET/CT,注射后1小时时间点采集,采用视觉评分与半定量指标(SUVmax、TBR)分析。

关键影像表现/征象

  • 视觉评估基于标准化评分系统判定29例中27例(93.1%)为阳性扫描。
  • 高摄取区域显示CXCR4表达,低摄取区域未见明显表达(数据未展示)。

诊断标准与关键数值

  • 视觉评估基于标准化评分系统:29例中27例(93.1%)为阳性。
  • 全组中位SUVmax为2.31(范围0.49-9.96),中位TBR为20(范围6.12-124.5)。
  • IV级病灶中位SUVmax 2.85显著高于III级病灶1.27(P=0.02)。
  • IV级病灶中位TBR 20与III级病灶22.37之间无显著差异。
  • 病理分析显示29例中III级5例(17.24%)、IV级24例(82.75%)。

临床应用与阅片要点

  • 68Ga-Cixafor™ PET/CT可在MRI后2周内、注射后1小时进行,采用视觉评分与SUVmax、TBR半定量分析。
  • 报告时需注意TBR在III级与IV级之间无显著差异,而SUVmax在IV级显著高于III级。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: While magnetic resonance imaging (MRI) remains the gold standard for morphological imaging, its ability to differentiate between tumor tissue and treatment-induced changes on the cellular level is insufficient. Notably, glioma cells, particularly glioblastoma multiforme (GBM), demonstrate overexpression of chemokine receptor-4 (CXCR4). This study aims to evaluate the feasibility of non-invasive 68Ga-Cixafor™ PET/CT as a tool to improve diagnostic accuracy in patients with high-grade glioma.

METHODS: In this retrospective analysis, a database of histopathology-confirmed glioma patients with MRI findings consistent with high-grade gliomas was utilized. Within 2 weeks of their MRI, these patients underwent 68Ga-Cixafor™ PET/CT scans to assess CXCR4 expression. Both visual scoring based on established criteria and semi-quantitative measures including maximum standardized uptake value (SUVmax) and tumor-to-background ratios (TBR) were calculated to analyze the PET/CT data.

RESULTS: Our retrospective study enrolled 29 histologically confirmed glioma patients with MRI findings consistent with high-grade gliomas. All patients underwent 68Ga-Cixafor™ PET/CT scans within 2 weeks of their MRI, specifically at one-hour post-injection time point. Visual assessment based on a standardized scoring system identified 27 positive scans out of 29 (93.1%). Median SUVmax was 2.31 (range: 0.49-9.96) and median TBR was 20 (range: 6.12-124.5). Pathological analysis revealed 5 grade III (17.24%) and 24 grade IV (82.75%) lesions among the 29 patients. Notably, the median SUVmax of grade IV lesions (2.85) was significantly higher than grade III lesions (1.27) (P=0.02). Conversely, there was no significant difference in median TBR between grade IV (20) and grade III (22.37). These findings support the correlation between high CXCR4 expression, particularly in high-grade gliomas, and elevated uptake of 68Ga-Pentixafor. While areas with high uptake showed CXCR4 expression, areas with low uptake did not exhibit noticeable expression (data not shown).

CONCLUSION: This study demonstrated that 68Ga-Cixafor™ PET exhibits a TBR with minimal cortical uptake, significantly enhancing glioma detection compared to conventional imaging methods. This, combined with the potential therapeutic capabilities of CXCR4-targeting radiopharmaceuticals, highlights the promise of 68Ga-Cixafor™ as a valuable tool for not only improved glioma diagnosis but also personalized treatment strategies.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Dadgar H, Norouzbeigi N, Assadi M, et al. A Prospective Evaluation of Chemokine Receptor-4 (CXCR4) Overexpression in High-grade Glioma Using 68Ga-Pentixafor (Pars-Cixafor™) PET/CT Imaging. Acad Radiol. 2024. PMID: 39690071. doi:10.1016/j.acra.2024.11.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。